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Articles

Antibiotic prophylaxis in the surgical management of
miscarriage in low-income countries: a cost-effectiveness
analysis of the AIMS trial
Ilias Goranitis, David M Lissauer, Arri Coomarasamy, Amie Wilson, Jane Daniels, Lee Middleton, Jonathan Bishop, Catherine A Hewitt,
Andrew D Weeks, Chisale Mhango, Ronald Mataya, Iffat Ahmed, Olufemi T Oladapo, Javier Zamora, Tracy E Roberts

Summary

Background There is ongoing debate on the clinical benefits of antibiotic prophylaxis for reducing pelvic infection after
miscarriage surgery. We aimed to study the cost-effectiveness of antibiotic prophylaxis in the surgical management of
miscarriage in low-income countries.
Methods We did an incremental cost-effectiveness analysis using data from 3412 women recruited to the AIMS trial,
a randomised, double-blind, placebo-controlled trial designed to evaluate the effectiveness of antibiotic prophylaxis in
the surgical management of miscarriage in Malawi, Pakistan, Tanzania, and Uganda. Economic evaluation was done
from a health-care-provider perspective on the basis of the outcome of cost per pelvic infection avoided within 2 weeks
of surgery. Pelvic infection was broadly defined by the presence of clinical features or the clinically identified need to
administer antibiotics. We used non-parametric bootstrapping and multilevel random effects models to estimate
incremental mean costs and outcomes. Decision uncertainty was shown via cost-effectiveness acceptability frontiers.
The AIMS trial is registered with the ISRCTN registry, number ISRCTN97143849.
Findings Between June 2, 2014, and April 26, 2017, 3412 women were assigned to receive either antibiotic prophylaxis
(1705 [50%] of 3412) or placebo (1707 [50%] of 3412) in the AIMS trial. 158 (5%) of 3412 women developed pelvic
infection within 2 weeks of surgery, of whom 68 (43%) were in the antibiotic prophylaxis group and 90 (57%) in the
placebo group. There is 97–98% probability that antibiotic prophylaxis is a cost-effective intervention at expected
thresholds of willingness-to-pay per additional pelvic infection avoided. In terms of post-surgery antibiotics, the
antibiotic prophylaxis group was US$0·27 (95% CI –0·49 to –0·05) less expensive per woman than the placebo
group. A secondary analysis, a sensitivity analysis, and all subgroup analyses supported these findings. Antibiotic
prophylaxis, if implemented routinely before miscarriage surgery, could translate to an annual total cost saving of up
to $1·4 million across the four participating countries and up to $8·5 million across the two regions of sub-Saharan
Africa and south Asia.
Interpretation Antibiotic prophylaxis is more effective and less expensive than no antibiotic prophylaxis. Policy
makers in various settings should be confident that antibiotic prophylaxis in miscarriage surgery is cost-effective.
Funding UK Medical Research Council, Wellcome Trust, and the UK Department for International Development.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license.

Introduction
Globally, about 210 million pregnancies are estimated to
occur annually, 90% of which are in low-income countries.1
Almost 84 million (40%) of these pregnancies end in
either miscarriage or induced abortion, in about equal
proportions.2,3 National and international guidelines on
the surgical management of induced abortion advocate
the use of antibiotic prophylaxis to reduce the risk of
infection.4–6 These guidelines are underpinned by strong
evidence on the clinical effectiveness of prophylactic
antibiotics given before surgical abortion.7
By contrast, sufficient evidence to support the routine
use of antibiotic prophylaxis in the surgical management
of miscarriage is scarce,8 and current guidelines do not
recommend the use of antibiotics before miscarriage

surgery, unless there is evidence of infection.9 Surgical
removal of miscarriage tissues is a most common method
of miscarriage management,10 particularly in low-income
countries where it represents up to 70% of all gynae
cological admissions.11 Infection is a serious complication
of miscarriage surgery and occurs in up to 30% of women
in low-income countries,12 with potentially significant mor
bidity and mortality implications.13,14 There is an urgent
need for a more comprehensive evaluation of the potential
role of antibiotic prophylaxis in this context,8 which has the
potential to offer significant clinical and economic benefits
to health systems globally.
In response to this, the Antibiotics In Miscarriage
Surgery (AIMS) trial was jointly funded by the UK
Medical Research Council, the Wellcome Trust, and the
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Research in context
Evidence before the study
In low-income countries, the surgical removal of miscarriage
tissues is the most common method of miscarriage management.
To date, national and international guidelines on the surgical
management of miscarriage do not recommend the use of
prophylactic antibiotics to reduce the risk of pelvic infection.
Infections after miscarriage surgery are frequent in low-income
settings and have been associated with clinically significant
morbidity and mortality implications. A Cochrane review showed
no previous high quality evidence of effectiveness, with four small
single-centered studies showing no significant benefit from
prophylactic antibiotics. The AIMS trial provided evidence on the
role of antibiotic prophylaxis in miscarriage surgery.

in women undergoing surgical management of miscarriage
in low-income settings. We find that antibiotic prophylaxis in
the surgical management of miscarriage is cost-effective and
provides substantial economic and health benefits.
Implications of all the available evidence
For clinicians and policy makers there is now evidence of both
clinical and cost-effectiveness. Our interpretation is that this
new evidence should result in the recommendation that, in
low-resource settings, antibiotic prophylaxis should be
administered before miscarriage surgery. Guidelines on the
management of miscarriage should be updated on the basis of
this evidence.

Added value of this study
To our knowledge, this study is the first to assess the
cost-effectiveness of antibiotic prophylaxis relative to placebo

UK Department for International Development, as part
of the Joint Global Health Trials Scheme, to evaluate the
effectiveness of antibiotic prophylaxis during the surgical
management of miscarriage in low-income countries.
Here, we use data from the AIMS trial to determine
the relative cost-effectiveness of antibiotic prophylaxis
compared with placebo in the surgical management
of miscarriage based on the outcome of cost per pelvic
infection avoided within 2 weeks of surgery.

Methods

Study design and participants
The AIMS trial was a multinational randomised, doubleblind, placebo-controlled trial. Detailed information
about the trial design and participants can be found in
the published trial protocol15 and the clinical paper.16
Briefly, 3412 women with a spontaneous miscarriage
(<22 weeks’ gestation) undergoing surgical management
of miscarriage with manual vacuum aspiration, suction
curettage, or sharp curettage, and who were willing and
able to provide informed consent, were recruited across
13 hospitals in Malawi, Pakistan, Tanzania, and Uganda
between June, 2013, and April, 2017. Women were
excluded from the study if they were younger than
16 years or had induced abortion of pregnancy, septic
miscarriage or evidence of infection, allergy to
prophylactic antibiotics (ie, doxycycline or metronidazole),
used antibiotics within 7 days before randomisation,
febrile illness, other contraindication to doxycycline and
metronidazole, or a condition requiring immediate care,
such as severe haem
orrhage. Women were randomly
assigned (1:1), using a secure internet facility, to receive a
single preoperative dose (about 2 hours before surgery)
of doxycycline (400 mg oral) and metronidazole (400 mg
oral) or identical placebos. Although obesity is a key
factor in the choice of dosage of prophylactic antibiotics
in high-income countries, obesity was not an issue in the
e1281

AIMS trial and, therefore, it was not formally considered.
Women were asked to attend an in-person follow-up
assessment on day 14 after treatment. No further formal
assessment was made in participants who attended for
this day 14 assessment. Those who did not attend were
prompted by telephone (to themselves or their nominated
contact person) to attend at a time convenient for them,
or were offered in-person visits to their home address to
minimise loss to follow-up. These additional attempts to
contact those who did not attend for follow-up were
permitted until day 28. Ethics approval was granted from
the Liverpool School of Tropical Medicine Research
Ethics Committee in the UK, the College of Medicine
Research and Ethics Committee in Malawi, the National
Council for Science and Technology in Uganda, the
Ifakara Health Institute in Tanzania, and the Aga Khan
University in Pakistan.

Effectiveness outcome
The outcome of the AIMS trial was pelvic infections
avoided within 2 weeks of surgery. As per trial protocol,
pelvic infection was determined in the presence of two or
more of the following clinical features: purulent vaginal
discharge, pyrexia (>38°C), uterine tenderness on
examination, and white cell count of more than 12 × 10⁹
cells per L, with no other recognised cause of infection, or
only one of these four clinical features if there was a
clinically identified need to administer antibiotics for the
treatment of a presumed pelvic infection.

Resource use and costs
Resource use information was collected prospectively
via case report forms. Forms were completed on at least
one occasion before discharge after surgery, at every
contact assessment during the follow-up period, daily
whilst an inpatient, and at final assessment. Resource
use information was collected from the perspective of
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the health-care provider and included antibiotics and
medications related to pain, allergy, diarrhoea, vomiting,
nausea, malaria, and fever as well as inpatient hospital
stays, outpatient visits, laboratory examina
tions, and
treatment of complications for which antibiotic prophy
laxis could potentially offer a clinical benefit. Such
complications were haemorrhage requiring blood trans
fus
ion, repeat uterine evacuation, and ana
phylaxis.
Other rare complications, such as uterine perforations,
were not considered as they do not relate to antibiotic
prophylaxis and were expected to equally appear in both
groups of the trial.
We calculated the cost associated with the use of
antibiotics and other commonly prescribed medications
on the basis of established dosage regimens and patientspecific duration of treatment. Mean unit costs were
obtained from the International Drug Price Indicator
Guide,17 which is recommended as the principal source
for medication costs in low-income and middle-income
settings.18 An adjustment of 25% was used to account
for shipping, handling, and internal distribution costs
(table 1).18,19 Country-specific and hospital-specific unit
cost estimates for secondary and tertiary patient services
in each participating country were obtained from the
WHO-CHOICE initiative.20 We used other secondary
sources to estimate the cost of laboratory examinations
and treatment of relevant complications.21–25 For women
requiring blood transfusion, we used unit cost estimates
for hospital-based blood transfusion services.22,23 Appro
priate cost estimates for repeat surgical removal of
pregnancy tissues were used according to whether the
surgery was done using dilatation and curettage or
manual vacuum aspiration.24,25 All non-medication-related
unit costs used in the analysis are shown in table 2.
To standardise unit costs across countries in cases where
data were not available, an index table was used to indicate
the relative mean cost of tertiary and secondary inpatient
and outpatient hospital services for each country-pair
in the study, based on the WHO-CHOICE estimates
(appendix p 1). This market-basket approach was used in
the Disease Control Priorities Project that aimed to inform
disease control priorities in low-income countries using
economic evaluation,18 and it is an established costing
method for the development of a complete set of countryspecific unit cost data in multinational trials.26 All
unit costs were adjusted to 2016 US$ using the average
US inflation rate between the price base year used in
individual studies and 2016, as recommended when there
is a relatively high proportion of imported commodities
in economic analyses.27 Given that the follow-up period
was 2 weeks, costs were not discounted.

Statistical analysis
Evidence suggests that health-care service provision and
patient outcomes differ across different hospitals within
one country and across countries,28 with these differences
being particularly profound in low-income settings.

Unit cost
Antibiotic prophylaxis

$0·091

Pain
Mild

$0·049

Moderate

$0·093

Severe

$0·835

Allergy
Mild

$0·010

Moderate

$0·103

Severe

$1·614

Diarrhoea
Mild

$0·551

Moderate

$3·849

Severe

$5·361

Vomiting
Mild

$0·036

Moderate

$0·641

Severe

$5·239

Fever*
Mild

$0·049

Moderate

$0·049

Severe

$0·049

Nausea
Mild

$0·036

Moderate

$0·855

Severe

$1·768

Malaria
Mild

$0·434

Moderate

$1·713

Severe

$1·980

Infection
Mild

$0·063

Moderate to severe

$1·693

Source: International Drug Price Indicator Guide (2015).17 *Main treatment is
reflected on antibiotics use and investigations.

Table 1: Medication-related unit costs by severity (US$, 2016 price base)
See Online for appendix

Thus, owing to the multinational nature of the AIMS
trial and the differences identified in costs and clinical
outcomes across countries and hospitals, we used a
multilevel random effects model to estimate the
differences in mean costs and outcomes between the
antibiotic prophylaxis and placebo trial groups. Multilevel
modelling accounts for unobserved hospital-specific and
country-specific effects on costs and outcomes and allows
for the estimation of cost-effectiveness across the whole
sample and for the individual participating countries.29
We did an incremental cost-effectiveness analysis to
compare the costs and outcomes associated with the
two groups of the trial. To account for the inherent
uncertainty around cost-effectiveness point estimates,
we used non-parametric bootstrapping with multilevel
models to generate 1000 paired estimates of incremental
mean costs and outcomes adjusted for age, marital
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Malawi

Pakistan

Tanzania

Uganda

References

Hospital services*
Inpatient stay
Per day in tertiary hospital

$4·41

$13·76

$8·38

$6·58

20

Per day in secondary hospital

$3·23

$10·08

$6·13

$4·81

20

Per day in tertiary hospital

$1·22

$2·64

$2·45

$2·15

20

Per day in secondary hospital

$0·83

$1·78

$1·65

$1·45

20

White cell count

$1·10

$3·18

$2·10

$1·69

21

Vaginal swab

$0·76

$2·19

$1·45

$1·17

21

Blood culture

$2·73

$7·89

$5·21

$4·20

21

Urinalysis

$1·00

$2·89

$1·91

$1·54

21

$20·02

$58·45

$21·35

$31·03

22, 40

$18·25

$46·60

$34·81

$28·07

24, 25

$3·99

$18·05

$7·61

$6·14

24, 25

Outpatient visit

Role of the funding source

Laboratory examinations

Complications
Hospital-based blood transfusion (per unit
of transfusion-ready blood)
Repeat evacuation
Dilatation and curettage
Manual vacuum aspiration

*These estimates only show the accommodation component of hospital costs; ie, excluding the cost of drugs
and diagnostic tests but including personnel, capital, and food costs.
Table 2: Other resource use categories and associated unit costs (US$, 2016 price base)

status, gestational age, previous miscarriage or stillbirth,
evidence of induced abortion, HIV status, type of
miscarriage surgery, cadre of surgeon (ie, specialist
doctor, non-specialist doctor, or non-physician, including
midwives, nurses, and other clinical staff), and residential
characteristics. We used the bootstrapping results to
derive cost-effectiveness acceptability frontiers,30 which
plot the probability of the optimal strategy being costeffective across a range of values of willingness-to-pay
per additional unit of outcome (ie, per pelvic infection
avoided within 2 weeks of surgery).
The economic evaluation relied on available case
analysis since only 74 (2%) of 3412 women were
censored at 2 weeks follow-up. Given that group
allocation was found to be a predictor of missingness
in the AIMS trial data (ie, women in the antibiotic
prophylaxis group were more likely to be missing),16 we
did an additional multiple imputation analysis under
the assumption that data were missing not at random.
Although in this clinical context it was expected that
censored women did not develop any pelvic infection,
the analysis was done under the assumption that all
censored women developed pelvic infection as a worstcase scenario. The multiple imputation was done using
chained equations.31 Differences between the antibiotic
prophylaxis group and placebo in terms of mean costs
and outcomes from the 10 multiply imputed datasets
were obtained according to Rubin’s rules,32 using
multilevel random effects models.33,34
We did subgroup analyses to assess the relative costeffectiveness of antibiotic prophylaxis for each part
icipating country, for the different types of miscarriage
e1283

(incomplete and missed miscarriage), for the different
types of miscarriage surgery (manual vacuum aspira
tion, suction curettage, sharp curettage), and for different
gestational age groups (<12 weeks and ≥12 weeks). To
assess the robustness of the main study findings, we did a
sensitivity analysis using published regional unit cost
estimates for each participating country (appendix p 2).18
We used Stata (version 14.2MP) for all analyses.
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had full access to
all the data in the study and had final responsibility for
the decision to submit for publication.

Results
Between June 2, 2014, and April 26, 2017, 3412 women
with a median age of 25 years (IQR 18–31) were recruited
across Malawi (2145 [63%] of 3412), Pakistan (353 [10%]),
Tanzania (210 [6%]), and Uganda (704 [21%]), and were
assigned to receive either antibiotic prophylaxis
(1705 [50%] of 3412) or placebo (1707 [50%] of 3412). Of
the 3412 women recruited, 2876 (84%) were married,
2352 (69%) lived in an urban area, and 2086 (61%) were
unemployed or in a housewife role. In terms of
residential characteristics, 1060 (31%) women were
living in rural areas, 589 (17%) had a flushing toilet, and
772 (23%) had non-shared piped and tapped water.
1262 (37%) of 3412 reported that they had problems
getting the food they need sometimes or more often.
696 (21%) of 3412 women had previously had a
miscarriage or stillbirth. Further information is available
in the appendix (p 3).
158 (5%) of 3412 women developed pelvic infection
within 2 weeks of surgery. Of these women, 68 (43%)
were in the antibiotic prophylaxis group and 90 (57%)
in the placebo group. The absolute risk difference be
tween antibiotic prophylaxis and placebo per woman was
–1·3% (95% CI –2·8 to 0·2; table 3). The strict defini
tion of pelvic infection using the clinical criteria only
(ie, excluding presumed infections in the presence of one
clinical feature) resulted in a significant difference in the
risk of pelvic infection between the two groups at the
5% level (risk ratio 0·60 [95% CI 0·37–0·96]; p=0·03).16
The clinical findings of the AIMS trial have been
published in full elsewhere.16
The resource utilisation per group is shown in the
appendix (p 4). Post-surgery antibiotics prescribed for
pelvic or other infections, such as urinary tract infection
and respiratory infection, were the biggest driver of costs,
accounting for about 50% of the total cost in the two
groups of the trial (table 3). In terms of post-surgery
antibiotics, the antibiotic prophylaxis group was US$0·27
(95% CI 0·05–0·49) less expensive per woman relative to
the placebo group. This finding is explained by the
additional days of infection (about 180 days), and possibly
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Antibiotic prophylaxis Placebo (n=1680);
raw mean (SD)
(n=1660); raw mean
(SD)

Difference (antibiotic prophylaxis – placebo)

Adjusted mean*

Normal-based
95% CIs†

Normal-based
95% CIs†

Mean per-woman costs (US$)
Pre-surgery prophylactic antibiotics

0·084 (0·000)

0·000 (0·000)

0·084

··

··

Post-surgery antibiotics

0·797 (2·964)

1·068 (3·535)

–0·270

–0·490

–0·050

Other medications

0·176 (1·603)

0·212 (2·593)

–0·031

–0·179

0·117

Laboratory examinations

0·113 (0·499)

0·154 (0·730)

–0·045

–0·086

–0·005

Complications

0·152 (1·678)

0·262 (3·274)

–0·121

–0·308

0·066

Hospital services

0·280 (2·452)

0·385 (2·406)

–0·112

–0·287

0·063

Total cost (country-specific unit cost estimates)

1·601 (6·419)

2·082 (8·564)

–0·496

–1·019

0·026

Total cost (regional unit cost estimates)

2·350 (12·548)

3·040 (14·803)

–0·718

–1·693

0·257

0·041 (0·198)

0·054 (0·225)

–0·013

–0·028

0·002

Risk of pelvic infection

*Adjusted for age, marital status, gestational age, previous miscarriage or stillbirth, evidence of induced abortion, HIV status, type of miscarriage surgery, surgeon, and
residential characteristics. †CIs calculated via bias-corrected and accelerated bootstrapping (1000 replications).

Table 3: Mean per-woman costs (US$, 2016 price base) and risk of pelvic infection

A

Probability cost-effective

1·0
0·8
0·6
0·4
0·2
0

B
1·0
Probability cost-effective

more severe cases of infections, in the placebo group.
Hospital-services-related costs were the second largest
driver of costs, accounting for about 20% of the total costs.
This finding is due to the 150 days of inpatient stay (53% of
which were in the placebo group) and 164 outpatient visits
(61% of which were in the placebo group) during the trial.
The antibiotic prophylaxis group was $0·50 (95% CI
0·03–1·02) less expensive per woman than the placebo
group was. In a sensitivity analysis, using the regional
unit cost, estimates increased the mean per woman cost
difference to $0·72 (95% CI 0·26–1·69).
The antibiotic prophylaxis group was more effective and
less expensive than the placebo group was (dominant
intervention). The figure shows the probability of anti
biotic prophylaxis being cost-effective across a range of
willingness-to-pay values per additional pelvic infection
avoided in the main and secondary analyses. Antibiotic
prophylaxis has a more than 80% probability of being
cost-effective for any willingness-to-pay value below
$20 per pelvic infection avoided (figure). According to
WHO, for highly cost-effective interventions, decision
makers should be willing to pay the country’s per capita
gross domestic product (GDP) for an additional disabilityadjusted life-year (DALY) avoided.35 Other sources recom
mend that this willingness-to-pay in low-income settings
should be a maximum of 50% of the per capita GDP.36
Thus, according to these sources, decision makers in the
trial context should be willing to pay up to $224 (50% of
the weighted per capita GDP) or $566 (weighted per capita
GDP) for one DALY avoided (appendix p 5). Pelvic
infections have a disability weight of 0·169,37 and are
known to last up to 2 weeks, which results in 0·0065 DALYs.
If decision makers are willing to pay $224 or $566 per
DALY averted, this payment equates to $1·45 or $3·67 for
0·65% of a DALY. At these willingness-to-pay values per
pelvic infection avoided, there is 97–98% probability

0·8
0·6
0·4
0·2
0

0

2

4

6

8

10

12

14

16

18

20

Willingness to pay (US$ per pelvic infection avoided)

Figure: Cost-effectiveness acceptability frontier indicating the probability of
antibiotic prophylaxis being cost-effective across different willingness-to-pay
thresholds per pelvic infection avoided in the main (available case) analysis (A)
and secondary (multiple imputation or worst-case scenario) analysis (B)
The dashed lines show the expected decision maker’s willingness-to-pay for a
pelvic infection avoided, as estimated from Woods and colleagues35 (blue line)
and the WHO recommendations (green line).36

that antibiotic prophylaxis is a cost-effective intervention
(figure A). In the secondary, worst-case scenario analysis,
where all censored women were assumed to have pelvic
infection, antibiotic prophylaxis had 88–89% probability
of being cost-effective (figure B). The downward slopes of
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the figure show that decision uncertainty is mainly driven
by costs rather than outcomes. The conclusions drawn
from the cost-effectiveness analysis were robust to the
regional (sensitivity) analysis and all subgroup analyses,
including the estimation of cost-effectiveness within each
participating country (appendix p 6).

Discussion
This study assessed the cost-effectiveness of antibiotic
prophylaxis relative to placebo in women undergoing
surgical management of miscarriage in low-income
settings. The findings show that the provision of anti
biotic prophylaxis before miscarriage surgery results
in fewer pelvic infections within 2 weeks of surgery
and lower costs than the current practice of no anti
biotic prophylaxis. Our analysis concluded that there
is a 97–98% probability that antibiotic prophylaxis is
a cost-effective intervention at expected thresholds of
willingness-to-pay per additional pelvic infection avoided.
This finding could translate to an annual total cost saving
of up to $1·4 million if antibiotic prophylaxis was
used routinely before miscarriage surgery across the
four participating countries (Malawi, Pakistan, Tanzania,
and Uganda) and a saving of up to $8·5 million across
the two regions (sub-Saharan Africa and south Asia;
appendix p 7).
Antibiotic resistance is a key global threat and reducing
the unnecessary and inappropriate use of antibiotics is a
global priority.38 However, we have shown that a single
prophylactic dose of antibiotics before miscarriage
surgery is an example of antibiotic usage that is both
necessary and appropriate, and that it also reduced
antibiotic usage after surgery.
To the best of our knowledge, this study is the first to
assess the relative cost-effectiveness of antibiotic prophyl
axis in the surgical management of miscarriage. The
study benefited from a large sample size recruited from
four low-income countries and 13 hospitals, a wide range
of primary data, and a high follow-up rate. However, the
study has some limitations. For pragmatic financial, time,
and trial burden-related reasons, extensive bottom-up
costing of all resource items was not done during the trial.
Although this decision probably increased the uncertainty
around the unit cost estimates used in the analysis, all
estimates were obtained from valid and reputable sources,
including the International Drug Price Indicator Guide,
WHO, and other secondary sources based on thorough
bottom-up costing. A sensitivity analysis using regional
cost estimates led to similar results, which supports the
generalisability of our findings.
In low-income settings, managing miscarriage
complica
tions can involve substantial out-of-pocket
expenses,39 such as travel expenses, formal or informal
expenses for outpatient services and inpatient care, and
time off work for women and their family members.
Given the emotionally distressing period after pregnancy
loss, these expenses were not captured in the trial to
e1285

avoid adding further burden to participants. Nevertheless,
the increased complication rates seen in the placebo
group suggest that these costs—in a societal perspective
of analysis—probably led to an even larger cost difference
between the two groups. Pelvic infections can also result
in longer-term effects, such as pelvic pain, ectopic
pregnancy, and infertility. Cost and disability effects
associated with these outcomes were not considered in
the analysis. However, given that pelvic infections
were more frequent in the placebo group, an exploration
of these costs and outcomes in a lifetime modelled
time-horizon would improve the cost-effectiveness of
antibiotic prophylaxis even further.
Finally, although only 74 (2%) of 3412 women were
censored at 2 weeks after miscarriage surgery, women in
the antibiotic prophylaxis group were more likely to be
missing. This finding could be attributed to the small
number of women lost to follow-up, or it might indicate
better effectiveness for antibiotic prophylaxis, but a worstcase scenario was used for analysis. For this calcula
tion, costs for censored women were multiply imputed
assuming the presence of pelvic infection. This analysis
concluded that, at expected thresholds of willingness-topay per additional pelvic infection avoided, there is 88–89%
probability that antibiotic prophylaxis is cost-effective.
Current international guidelines recommend the use of
prophylactic antibiotics in abortion surgery but not in
miscarriage surgery. Our findings lend strong support
on the cost-effectiveness of antibiotic prophylaxis before
miscarriage surgery. Policy makers in various settings
should be confident that providing prophylactic antibiotics
in the surgical management of miscarriage is a good use
of their restricted health-care budgets. Decision making
guidelines on miscarriage management should be up
dated to reflect the findings of this study and the efficacy
evidence from the AIMS trial.
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